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ABSTRACT 
 
After 40 years of research, in vitro systems for mammalian embryo 
production produce lower quality embryos than those derived from in vivo 
sources. Recent reports have demonstrated that in vitro bovine oocyte 
maturation systems benefit from the addition of oocyte secreted factors, 
specifically Bone Morphogenic Protein 15 (BMP15) from heterologous sources. 
However, known amino acid sequence variation and species-specific patterns of 
post-translational glycosylation lead us to hypothesize that utilization of bovine-
specific oocyte secreted factors would be more beneficial than the observed 
effects of heterologous factors.  
To test this hypothesis, wild type, bovine BMP15 was cloned using 
reverse transcriptase PCR from RNA obtained from bovine ovarian tissue. For 
improved detection and purification of the biologically active recombinant protein, 
a FLAG tag peptide sequence (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) was 
incorporated into the wild type BMP15 gene by PCR. This modified protein was 
cloned into the pCDNA 3 mammalian expression vector. HEK-293 (human 
embryonic kidney 293) and FBK (fetal bovine kidney) cell lines were transfected 
via electroporation and then selected to homogeneity.  
Collection and purification of rbFL-BMP15 from conditioned medium was 
accomplished by incubation with anti-FLAG affinity gel and the use of 3X FLAG 
peptide for elution. Peptides of 15.4 kDa and 17 kDa were noted from the human 
HEK-293 transfected cell line, while in contrast, bovine FBK cells produced a 
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single 17 kDa protein. Bioactivity and BMP receptor signaling specificity were 
ascertained using in vitro treatment of HeLa cells and Western blotting for the 
BMP signaling molecule phosphorylated-SMAD 1/5.  Inhibition of this signaling 
cascade using dorsomorphin, a selective bone morphogenic protein receptor I 
inhibitor, demonstrated the purified proteins served as BMP15-like agonists. 
To examine the impact of our purified, bovine-specific peptides on oocyte 
maturation, cumulus oocyte complexes were in vitro matured for 24 hours in the 
presence of 100 ng/ml recombinant human BMP15 or rbFL-BMP15 from human 
or bovine cell lines. Real time quantitative PCR analysis of BMP15 stimulated 
genes, PTGS2 and TSG6, revealed statistically significant increases in transcript 
level for treatment with human BMP15 by a Dunnett’s test (p<0.05). In this report, 
however, we failed to detect a significant affect of rbFL-BMP15 on the gene 
expression of in vitro mature cumulus oocyte complexes at 24 hours with 100 
ng/ml rbFL-BMP15. Future studies including differing time points and 
concentrations, along with the addition of GDF9 to form a possible heterodimer 
should be investigated for the possibility of improving bovine oocyte in vitro 
maturation.  
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CHAPTER I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
 
Utilization of ART in Cattle 
From the first successful embryo transfer in 1951, the use of assisted 
reproductive technologies (ART) in the bovine industry has expanded to become 
commonplace (Willett, Black, et al., 1951). Over 990,000 bovine embryos were 
transferred worldwide in 2010 as reported by the International Embryo Transfer 
Society’s (IETS) data retrieval committee. In vitro produced embryos are 
increasing their presence within the group with almost 340,000 transfers in 2010. 
This represents an increase of 11% over 2009, demonstrating an increasing 
trend for the use of in vitro maturation and fertilization in the bovine industry. 
According to the IETS, the United States produced almost 35,000 bovine 
embryos in vitro by transvaginal ultrasound-guided ovum pick up (OPU) and in 
vitro fertilization (IVF) in 2010 that resulted in more than 26,000 embryo 
transfers. These numbers followed the worldwide trend of increased in vitro 
embryo production. The 35,000 bovine embryos represent 6,876 OPU sessions 
that yielded 109,615 oocytes for subsequent in vitro maturation (IVM) followed 
by IVF. Based on these data, the efficiency of producing transferrable bovine 
embryos was only 32% in the United States, leaving ample room for 
improvement. 
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Following OPU, the oocytes must be taken through IVM, IVF and subsequent 
culture prior to embryo transfer. These processes include IVM, IVF and 
subsequent culture. Medium for IVF has developed into a relatively complex 
system that is customizable even to the individual sire used for fertilization 
(Parrish, Susko-Parrish, et al., 1988; Fukui, Sonoyama, et al., 1990). Work by 
Hansen et al. showed that fertilization rates remained unchanged in both Bos 
taurus and Bos indicus breeds exposed to heat stress despite a drastic drop in 
embryo production (Hansen, Drost, et al., 2001). This evidence points to 
fertilization rate as an unreliable measure of the1 developmental capacity of the 
mature oocyte. The percentage of oocytes developing beyond the resumption of 
gene transcription at the maternal to zygotic transition, occurring at the 8- to 16- 
cell embryo, and into blastocysts is a direct measurement of developmental 
competence (Telford, Watson, et al., 1990; Memili, Dominko, et al., 1998; King, 
Niar, et al., 1988). This competence is acquired in the antral phase of 
folliculogenesis prior to ovulation or during the period of IVM (Eppig, Schultz, et 
al., 1994). In contrast to medium developed for IVF, which can be customized for 
the sire, standard maturation medium is basic. Interest in improving in vitro 
maturation efficiency has recently increased with the development of a 
procedure entitled simulated physiological oocyte maturation or SPOM with two 
culture medias corresponding to peri-ovulatory (pre-IVM) and post-ovulatory 
(extended-IVM) development (Albuz, Sasseville, et al., 2010). During this time of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
This thesis follows the style of Reproduction 
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maturation, the oocyte receives nutrients and regulatory signals that are required 
for proper nuclear and cytoplasmic maturation (Ka, Sawai, et al., 1997; Chian & 
Sirard, 1995). Developmental competence of in vitro produced embryos is lower 
than those produced in vivo, in part due to inadequacies in the in vitro 
maturation culture system (Sutton, 2003; Rizos, Ward, et al., 2002).  
Recent work by Hussein et al. demonstrated the addition of oocyte secreted 
factors (OSFs) BMP15 (bone morphogenetic protein 15) and GDF9 (growth 
differentiation factor 9) to maturation medium increased the percentage of 
oocytes developing into blastocysts without affecting cleavage rates, providing 
evidence that these factors are capable of increasing developmental 
competence(Hussein, Thompson, et al., 2006). Following an observation that 
co-culture with denuded oocytes during IVM was beneficial for the COCs, 
exogenous ovine BMP15 was observed to have a similar effect with the intention 
of more closely mimicking the complex microenvironment of the follicle during 
the latter stages of folliculogenesis. 
In Vivo Follicular Development 
During a single estrous cycle antral follicles, which are marked by the 
formation of a fluid filled antrum, develop in several waves. The number of 
waves per cycle differs by species, but the preovulatory wave that begins with 
luteolysis is the only wave that will result in ovulation (Savio, Keenan, et al., 
1988; RAJAKOSKI, 1960). This final growth and development of an antral follicle 
consists of four major stages: recruitment, development, selection and atresia 
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(Eppig, Schultz, et al., 1994). This process begins when the hypothalamus with 
releases of gonadotropin releasing hormone (GnRH), which stimulates the 
anterior lobe of the pituitary gland to secrete the glycoprotein hormones follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) (Roche, 1996). 
Recruitment is marked by the growth of a group of follicles under the 
influence of increasing levels of FSH (Sunderland, Crowe, et al., 1994; Adams, 
Matteri, et al., 1992). FSH increases proliferation of the granulosa cells and is 
also responsible for directing the expression of luteinizing hormone (LH) 
receptors (Eppig, Wigglesworth, et al., 1997). These follicles begin to produce 
low levels of inhibin and estrogen. Inhibin negatively feeds back on the anterior 
lobe of the pituitary and selectively decreases the level of FSH, while estrogen 
increases the release of GnRH (Ginther, Bergfelt, et al., 2000b; Ginther, 
Bergfelt, et al., 2000a; Hillier, 1994; Sunderland, Crowe, et al., 1994). Recruited 
follicles will either continue to grow to dominance or become atretic and regress. 
(Fig. 1) 
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Figure 1 The pattern of FSH (blue), LH (green) and progesterone (yellow, P4) 
during the estrus cycle of Bos taurus cattle. Each wave of follicular growth is 
preceded by a transient rise in FSH concentrations. Healthy growing follicles are 
shaded in yellow, atretic follicles are shaded red. A surge in LH and FSH 
concentrations occurs at the onset of estrus and induces ovulation. The pattern 
of secretion of LH pulses during an 8 hour window early in the luteal phase 
(greater frequency, lesser amplitude), the mid-luteal phase (lesser frequency, 
lesser amplitude) and the follicular phase (high frequency) is indicated in the top 
panel. (Forde, Beltman, et al., 2011) 
 
 
 
The increasing level of estrogen produced by the dominant follicle reaches a 
threshold and stimulates the surge center of the hypothalamus to change the 
pulsitility of GnRH resulting in the preovulatory LH surge from the anterior 
pituitary (Sunderland, Crowe, et al., 1994; Forde, Beltman, et al., 2011). This LH 
surge decreases the release of estrogen by inducing a switch from the 
production of estrogen to progesterone in the dominant follicle and triggers the 
production of histamine and prostaglandin E2 (PGE2) (Acosta, Berisha, et al., 
1999; Espey, 1980). Under the influence of PGE2 blood flow increases locally 
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and histamine increases vascular permeability (Espey, 1980). As a result, the 
theca interna becomes edematous and follicular pressure increases. The surge 
ends proliferation of thecal and granulosa cells concurrent with the theca interna 
cellular transition to progesterone producing luteal cells and the formation of a 
corpus luteum (Gonzalez-Robayna, Falender, et al., 2000). Collagenase begins 
to break down the connective tissue and weakening the follicle at the same time 
as follicular pressure is increasing (Espey, 1980). Finally, the LH surge causes 
the ovary to produce prostaglandin F2α (PGF2α), which increases contractions 
of the smooth muscle of the ovary (Acosta, Berisha, et al., 1999). The stage is 
now set for ovulation, but there are significant and complex paracrine 
interactions occurring inside the follicle during this development in which the 
oocyte plays an active role in preparing for ovulation (Li, Norman, et al., 2000; 
Eppig, Wigglesworth, et al., 1997; Gilchrist, Ritter, et al., 2004). 
Bidirectional Cell Signaling in the Cumulus Oocyte Complex 
The importance of the entire cumulus oocyte complex became apparent in 
1967 when Biggers et al. reported the requirement for the metabolites from 
follicular cells for oocytes and zygotes (Biggers, Whittingham, et al., 1967). Gap 
junctions containing connexin43 channel proteins proved to be the lifeline 
between the cumulus somatic cells and the oocyte allowing for direct 
communication from birth through ovulation (Ackert, Gittens, et al., 2001). In 
fact, cumulus cell glycolysis is regulated by mRNAs expressed by the oocyte 
that encode glycolytic enzymes (Sugiura, Pendola, et al., 2005). With the 
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discovery of autocrine and juxtracrine growth factors such EREG (epiregulin) 
and AREG (amphiregulin), an increasingly complex microenvironment with two-
way communication began to emerge (Conti, Hsieh, et al., 2006). 
Oocyte secreted factors (OSFs) direct the actions of cumulus cells via a 
paracrine mechanism. In fact, folliculogenesis fails without these factors based 
on evidence provided by inactivating mutations of OSFs in sheep and mice 
(Gilchrist, Ritter, et al., 2004). These factors include members of the TGFβ 
(transforming growth factor β) and FGF (fibroblast growth factor) families 
including BMP6 (bone morphogenetic protein 6), BMP15, GDF9, and FGF8 
(fibroblast growth factor 8). Members of the TGFβ family, GDF9 and BMP15 
have proven to be important and are required for normal fertility (Galloway, 
McNatty, et al., 2000; Dong, Albertini, et al., 1996). 
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Figure 2 Model of oocyte-follicle cell interactions. How these interactions may 
interact to regulate oocyte maturation in vivo. The resumption of oocyte meiosis 
in vivo is a highly orchestrated, complex process that integrates oocyte 
paracrine signals with an array of maternal endocrine, granulosa/cumulus 
paracrine and gap-junctional signals. This highly integrated interaction between 
oocyte and follicular somatic cells is unlikely to occur during spontaneous IVM. 
Dotted arrows indicate signals of diminishing intensity. ‘X’ represents a 
hypothetical meiotic-inducing factor. R-SMADs represent receptor SMAD 
signaling molecules. Modified from (Gilchrist, 2010) 
 
 
 
Signaling gradients of OSFs GDF9 and BMP15, are crucial for maintaining 
the phenotypes of the granulosa and cumulus cells (Conti, Hsieh, et al., 2006; 
Gilchrist, Ritter, et al., 2004). These growth factors act in a paracrine fashion 
through BMP Receptor type II and ALK5/6 (transforming growth factor beta 
receptor 1, bone morphogenetic protein receptor type IB) receptor complex on 
cumulus cells followed by activation of the intracellular transcription factors 
R-SMADs 
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SMAD 1/5/8 (mothers against decapentaplegic homolog) or 2/3 by 
phosphorylation (Figure 2) (Kaivo-oja, Jeffery, et al., 2006). Specifically, in 
contrast to GDF9 signaling through SMAD 2/3, BMP15 activation of SMAD 1/5/8 
occurs by phosphorylation at serine residues 463 and 465 (Moore, Otsuka, et 
al., 2003). The activated glycosyl-SMAD 1/5/8 associates with the co-SMAD4 to 
form a complex that translocates to the nucleus and affects the expression 
profile of several genes through a variety of other transcription factors, co-
activators and co-repressors (Fig. 3) (Anderson & Darshan, 2008; Kaivo-oja, 
Jeffery, et al., 2006). These genes are associated with differentiation of 
granulosa cells to cumulus cells, maintenance of this phenotype by prevention of 
luteinization, and expansion of the COC in the developing antral follicle following 
the LH surge (Richards, Russell, et al., 2002). Cumulus cell expansion mediated 
by OSFs is carried out with the expression of multiple genes including 
prostaglandin-endoperoxide synthase 2 (PTGS2), hyaluronan synthase 2 
(HAS2), tumor necrosis factor, alpha-induced protein 6 (TNFAIP6) and pentraxin 
3 (PTX3) (Richards, Russell, et al., 2002; Li, Rajanahally, et al., 2009; Dragovic, 
Ritter, et al., 2005; Elvin, Clark, et al., 1999). It has also been shown that BMPs 
secreted by the oocyte actively prevent apoptosis in the cumulus cell layers 
(Hussein, Froiland, et al., 2005). 
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Figure 3 Bone morphogenic protein signaling. The BMPs bind to type I and II 
receptors and facilitate their association. The constitutively active kinase 
domains of type II receptors phosphorylate type I receptors, and this in turn 
activates the SMAD signaling pathway through phosphorylation of receptor 
SMADs (SMAD1, SMAD5 and SMAD8). These associate with co-SMADs 
(SMAD4) to form a heteromeric complex that translocates to the nucleus and 
stimulates the expression of a wide range of target genes. Modified from 
(Anderson & Darshan, 2008). 
 
 
 
PTGS2, also known as COX2 (cyclooxygenase 2), is the rate-limiting step in 
the synthesis of prostaglandins and is involved in the inflammatory response 
(Smith, DeWitt, et al., 2000). Along with PTX3 and TNFAIP6, which are also 
involved in the inflammation, these genes contribute to the expansion of the 
cumulus cells prior to ovulation (Richards, Russell, et al., 2002). HAS2 is a 
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component of the extracellular matrix and provides a framework for 
angiogenesis during wound healing along with inflammation. TNFAIP6 and 
HAS2 are two components of the extracellular matrix that the cumulus cells 
migrate on during expansion (Salustri, Camaioni, et al., 1999). The activation of 
these genes by OSF signaling pathways further demonstrates the active role the 
oocyte plays in folliculogenesis.   
Increased levels of cAMP have been shown to be important for the 
development of mammalian oocytes, particularly by maintaining meiotic arrest 
(Cho, Stern, et al., 1974). Shortly after the LH surge, gap junctions between 
somatic cumulus cells and the oocyte degrade. This degradation prevents the 
flow of cAMP and cGMP (3’-5’-cyclic adenosine monophosphate; cyclic 
guanosine monophosphate) from the cumulus cells from entering the oocyte. 
Natriuretic peptide type C (NPPC) produced by the mural granulosa cells binds 
to its associated receptor natriuretic peptide receptor 2 (NPR2) expressed by the 
cumulus cells to increase production of cGMP which is transferred to the oocyte 
by gap junctions to maintain meiotic arrest (Lee, Zhang, et al., 2013). The 
decrease in cGMP leads to an increase in PDE3 (phosphodiesterase 3A) in the 
oocyte, which hydrolyzes the remaining cAMP (Tsafriri, Chun, et al., 1996; Han, 
Vaccari, et al., 2006). Lower levels of cAMP, decrease the activity of 
phosphokinase A (PKA) (Tsafriri, Chun, et al., 1996). PKA normally keeps the 
phosphatase cell division cycle 25 homolog B (CDK25B) inactive and 
WEE1/myelin transcription factor 1 (WEE1/MYT1) actively phosphorylating 
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meiotic promoting factor (MPF) complex to keep it inactive (Han, Chen, et al., 
2005). Decreased PKA frees CDK25 to dephosphorylate the cyclin-dependent 
kinase 1 (CDK1) subunit of MPF. MPF then becomes active and releases the 
oocyte from meiotic arrest at the dictyate stage in late prophase I and it 
proceeds to metaphase II until fertilization (Duckworth, Weaver, et al., 2002; Han 
& Conti, 2006). Throughout this process the oocyte actively participates by not 
only directly influencing the development of the follicle but also maintaining the 
undifferentiated state of the surrounding cumulus cells (Li, Norman, et al., 2000; 
Hussein, Froiland, et al., 2005). The OSFs also regulate CC amino acid and 
energy substrate uptake and transport to the oocyte preserving the health of the 
oocyte itself (Makabe, Naguro, et al., 2006; Albertini, Combelles, et al., 2001; 
Sugiura, Pendola, et al., 2005) 
In Vitro Maturation 
Assisted reproductive technologies are commonplace in the bovine industry, 
but current in vitro systems for mammalian embryo production are inefficient 
when considering yield of transferrable embryos and produce embryos with 
lower viability than their in vivo derived counterparts (Greve, Xu, et al., 1987; 
Sutton, 2003; Rizos, Ward, et al., 2002). These developmental differences likely 
arise from the vastly different environments during final oocyte maturation. Upon 
removal from the dynamic follicular environment, the in vitro matured oocyte is 
placed in static culture medium that supplies only the critical components 
necessary for survival. In fact within 9 hours of in vitro culture the gap junction 
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communication between the oocyte and cumulus cells is lost, and the rate at 
which the connections are lost is dependent on the IVM medium (Thomas, 
Armstrong, et al., 2004; Thomas, Thompson, et al., 2004). As a result, the 
viability of the in vitro matured oocytes is compromised with only around 10% of 
the total cultured oocytes continuing development into an offspring as compared 
to almost 25% of in vivo matured oocytes (Gilchrist, 2010). Thus there is 
tremendous room for improvement of the culture media components and 
increased efficiency of the embryo production systems. 
The nuclear maturation process in vitro occurs spontaneously when the 
cumulus oocyte complex (COC) is removed from the restrictive environment of 
the follicle (Handel & Eppig, 1998; Eppig, 2001). The typical maturation medium 
consists of a tissue culture base with sodium pyruvate as an energy source, FBS 
as a protein source, FSH and LH. This medium is in stark contrast to the 
complexities of in vivo maturation described earlier. Generally, the immature 
oocyte is placed in this basic medium for a period of 20-24 hours during which 
time the cumulus cells begin to expand and the gap junctions break down. This 
accelerated process leads to a decrease in cAMP and a progression by the 
oocyte to metaphase II. Opportunity is decreased for the oocyte to attain proper 
cytoplasmic maturation and therefore the necessary RNAs and proteins to 
continue to develop until gene transcription resumes. 
The process of maturation is complex, requiring the participation of both the 
oocyte and its somatic neighbors (Handel & Eppig, 1998; Buccione, Schroeder, 
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et al., 1990). It is apparent that the oocyte’s role in the micro-environment of the 
developing follicle is important. For example, BMP15 and GDF9 null animals 
have been reported to have decreased fertility or be sterile(Dong, Albertini, et 
al., 1996; Davis, McEwan, et al., 1992; Galloway, McNatty, et al., 2000; Yan, 
Wang, et al., 2001) Gilchrist et al. reported a 1.4 fold increase in blastocyst rate 
in response to the addition of exogenous BMP15 to bovine maturation medium 
(Gilchrist & Thompson, 2007). In another study, the addition of two OSFs, 
BMP15 and GDF9, during bovine oocyte maturation in vitro also increased 
developmental competence, reflected by a 1.5 fold increase in blastocyst rate 
(Hussein, Thompson, et al., 2006).  
Post-Translational Modifications 
Protein synthesis involves translation of the mRNA sequence into a chain of 
amino acids known as a polypeptide through the utilization of trinucleotide 
codons (Wold, 1981). To initiate translation the small 40S subunit of the 
ribosome binds to the mRNA and scans specifically for the start codon sequence 
of AUG (Merrick & Hershey, 1996). The first transfer RNA (tRNA), which 
contains the antisense start codon bound to a methionine residue, is present in 
the 40S ribosome along with several eukaryotic initiation factors (eIFs) and is 
termed the 43S ribosome unit (Pestova, Borukhov, et al., 1998; Kozak, 1978). 
Following binding at the AUG start codon several eIFs are released and the 60S 
subunit joins the complex (Kozak, 1989). The ribosome complex consists of 
three sites for tRNA molecules termed A for aminoacyl, P for peptidyl and E for 
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exit. The first tRNA is in the P site when second tRNA bound to eukaryotic 
elongation factor 1α (eEF1α) and containing the antisense sequence to the next 
codon binds to the mRNA in the A site (Pestova, Borukhov, et al., 1998; Cigan, 
Feng, et al., 1988). The amino acid bound to the tRNA in the A site is now next 
to the methionine residue on the initiating tRNA. A peptide bond is formed at the 
carbonyl carbon of the residue in the P site with the amino terminus of the 
residue in the A site. The result is a dipeptide bound to the tRNA in the A site 
and a tRNA lacking an amino acid in the P site. 
The entire ribosome shifts 5’ to 3’ one 3 nucleotide frame and free tRNA is 
now located in the E site and can exit and be recycled. Another tRNA matching 
the next codon and bound to eEF1α moves into the A site and the process 
continues until the ribosome encounters a codon that has no complementary 
tRNA known as a stop codon (Valle & Morch, 1988). The stop codon can be one 
of three sequences: UAA, UAG or UGA. Eukaryotic release factor 1 (eRF1) 
enters the A site and termination of the peptide begins. eRF1 acts in 
combination with eRF3 to disassemble the ribosome complex and release the 
polypeptide (Stansfield, Jones, et al., 1995). 
Many proteins require modification, often cleavage by specific proteolytic 
enzymes, following translation to become biologically active (Schimke & Doyle, 
1970). These post translational modifications (PTMs), including phosphorylation, 
glycosylation, and methylation, require correct conformation of the polypeptide 
substrate to fit the binding sites of the enzymes (Neurath & Walsh, 1976; 
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Ottesen, 1967). Kinases attach phosphate groups to the hydroxyl groups of the 
amino acids serine, threonine and tyrosine (Wold, 1981). The phosphate groups 
are negatively charged and usually confer a change in the protein’s 
conformation. This conformation change often reversibly changes the activity of 
a protein and thus is a common mechanism for the regulation of protein activity 
(Taborsky, 1974; Wold, 1981)  
Glycosylation of the side chains of an amino acid with covalently bonded 
oligosaccharides is another type of PTM and is essential in yeast and higher 
eukaryotes with around 50% of human proteins glycosylated (Gentzsch & 
Tanner, 1996; Metzler, Gertz, et al., 1994; te Heesen, Janetzky, et al., 1992; 
Wong, 2005). These covalently bonded oligosaccharides can cause profound 
effects in a biological system (Wold, 1981). For example blood type antigens are 
determined by the difference in oligosaccharides on cell surfaces (Kabat, 
Bassett, et al., 1965; Anderson, Seno, et al., 1964; Adams, 1965; Creeth & 
Knight, 1967). Humans and old world monkeys lack 1,3-galactosyltransferase 
present in other mammals, thus the cells expressing α1,3-galactose 
glycosylation are seen as foreign and cause a hyperacute rejection in pig to 
human organ transplantation (Galili, Shohet, et al., 1988; Galili, 2001; Cooper, 
Koren, et al., 1993; Good, Cooper, et al., 1992). Many proteins that are 
membrane associated or secreted in eukaryotes are glycosylated in one of two 
fashions, N or O-linked (Ecker, Mrsa, et al., 2003). N-linked glycosylations are 
added co-translationally in the lumen of the endoplasmic reticulum (ER) while O-
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linked forms primarily manufactured in the Golgi apparatus (GA) (Schachter & 
Williams, 1982).  
N-Acetylglucosamine is linked to the amide of asparagine followed by any 
amino acid except proline or aspartate ahead of a serene or threonine (Helenius 
& Aebi, 2001; Kornfeld & Kornfeld, 1985). Peptides that have N-linked 
glycosylations are glycosylated beginning at the cytosolic face of the ER and 
continues as the peptide is transported through the ER and to the GA where 
glycosylation continues (Kornfeld & Kornfeld, 1985; Ungar, 2009).  
O-linked glycosylation generally involves β-galactosyl-α-N-
acetylgalactosamine covalently bonded to the hydroxyl group of serene or 
threonine, but can also be galactose, mannose or xylose (Schachter & Williams, 
1982). These modifications vary in size from a single galactose up to 1000 
disaccharide units. In the golgi apparatus, monosaccharide units are added to 
the side chains with corresponding glycosyltransferases. The locations of O-
linked oligosaccharides are not determined by amino acid sequence as in the N-
linked form but are specified by the secondary and tertiary structure of the 
protein (Bause & Lehle, 1979). The secondary structure results from the pattern 
of hydrogen bonds between the backbone amino and carboxyl group and 
consists most often of α helices and β sheets while the tertiary structure refers to 
the three-dimensional arrangement of the secondary structures (Perutz, 1976; 
Urry, 1968; Nobbs, Watson, et al., 1966). 
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A single protein can have multiple N and O-linked glycosylation events. In 
some cases glycoproteins that lack a certain modification still appear to be 
functional but other times the oligosaccharide bonds affect structure, stability 
and activity. Since N-linked glycosylations are added co-translationally, the 
structures often determine the folding of the processed protein and can add 
stability by decreasing the protein’s flexibility. O-linked glycosylations may stiffen 
the peptide backbone of the protein and cause extension of the overall length. 
Since glycosylation occurs without a template, unlike RNA transcription or 
proteins translation, and the GA contains over 200 glycosylation enzymes, the 
production of glycosylated proteins is heterogeneous (Ungar, 2009). The 
heterogeneity poses an important problem if their interaction with another 
molecule, such as an enzyme, requires a specific interaction. In order to 
decrease the heterogeneity of the modified proteins, many cell types express a 
restricted subset of enzymes for glycosylation that are further segregated 
throughout the GA to form production lines (Dunphy, Fries, et al., 1981; 
Spooncer, Fukuda, et al., 1984). The cell specific expression of post-
translational enzymes together with the difference in modifications between 
species points to the importance of cell type selection producing biologically 
active recombinant proteins. Of particular note, a recent report by Hashimoto, 
Moore and Shimaski provided evidence of N-linked glycosylation of recombinant 
mouse BMP15 but not human BMP15 produced in HEK-293 cells (Hashimoto, 
Moore, et al., 2005). 
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Figure 4 Sequence alignment of human, bovine and ovine BMP15 using Clustal 
Omega (Conway Institute, University College Dublin, Dublin, Ireland). Bovine 
and human sequences share 75% identity. BMP15 Cleavage site is highlighted 
red. Identical residues (*), conserved residues with similar properties (:) 
conserved residues with weakly similar properties (.) 
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Research Rationale 
After over 40 years of research, current in vitro systems for mammalian 
embryo production produce lower quality embryos than those derived in vivo 
(Sutton, 2003; Rizos, Ward, et al., 2002). Recent reports demonstrate that in 
vitro bovine oocyte maturation systems benefit from the addition of oocyte 
secreted factors, specifically GDF9 and BMP15 from heterologous from sources 
(sheep or mouse) (Hussein, Thompson, et al., 2006; Gilchrist & Thompson, 
2007). The difficulty of acquiring OSFs has been a hindrance for this area of 
research. There is currently one company that markets recombinant human 
BMP15 and mouse GDF9. In contrast to other members of the TGFβ family of 
proteins, BMP15 and GDF9 have relatively low homology across species and 
the differences are located in structurally significant locations (Al-Musawi, 
Walton, et al., 2013). In fact, differences in amino acid sequence of the pro-
region have been shown to affect the expression and processing of GDF9 and 
BMP15 (Simpson, Stanton, et al., 2012; Al-Musawi, Walton, et al., 2013). Due to 
known amino acid sequence variation (Fig. 4) and species-specific alterations in 
post-translational glycosylation of mature proteins, we hypothesize that 
utilization of species-specific oocyte secreted factors will be more beneficial than 
the observed effects of heterologous factors. We propose to produce purified 
recombinant bovine BMP15 from homologous and heterologous cell lines and 
test the efficiency against commercially available human BMP15. The choice to 
target BMP15 is based on the results of blastocyst rate after IVM with the 
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addition of recombinant OSFs where exogenous BMP15 increased the yield by 
1.5 fold, but the addition of GDF9 alone or in combination did not increase the 
blastocyst rate, and therefore, developmental competence. The long-term goal 
of this work is to produce species-specific recombinant oocyte secreted factors 
capable of improving mammalian embryo production in vitro. Furthermore, the 
utilization of purified, recombinant protein will allow careful evaluation of cumulus 
and oocyte specific responses to these factors during a critical time of gamete 
and embryo development. 
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 CHAPTER II 
CONSTRUCTION OF RECOMBINANT BOVINE FLAG-BONE 
MORPHOGENIC PROTEIN 15 
 
Introduction 
After over 40 years of research, current in vitro systems for mammalian 
embryo production have been shown to produce lower quality embryos than 
those derived from in vivo sources (Sutton, 2003; Rizos, Ward, et al., 2002). 
Recent reports have demonstrated that in vitro bovine oocyte maturation 
systems benefit from the addition of oocyte secreted factors, specifically GDF9 
and BMP15 from heterologous from sources (sheep or mouse) (Gilchrist & 
Thompson, 2007; Hussein, Sutton-McDowall, et al., 2011; Hussein, Thompson, 
et al., 2006). However, known amino acid sequence variation and species-
specific alterations in post-translational glycosylation of mature proteins lead us 
to hypothesize that utilization of species-specific oocyte secreted factors would 
be more beneficial than the observed effects of heterologous factors (Simpson, 
Stanton, et al., 2012; Al-Musawi, Walton, et al., 2013). Commercial availability of 
recombinant BMP15 was limited to human origin. In order to test the efficacy in 
vitro, the development of a system for the production and purification of 
recombinant bovine BMP15 was essential.  
The goal of this work was to produce a species-specific recombinant 
oocyte secreted factor with the potential to improve mammalian embryo 
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production in vitro. We hypothesized that due to amino acid sequence 
divergence and species-specific post-translational glycosylation, homologous 
BMP15 will be more effective at directing bovine oocyte development during in 
vitro maturation than heterologous BMP15. To test this hypothesis, we first 
needed to devise a production and purification system for the recombinant 
bovine BMP15 (rbBMP15). To accomplish this objective we collected mRNA, 
amplified and modified the transcript via PCR site-directed mutagenesis, 
subcloned the sequence into an expression vector and transfected mammalian 
cell lines. Protein was then collected from the cell lines’ supernatants and 
purified using affinity chromatography. 
Based on work published by Li, Rajanahally, et al., (2009) we made 
several modifications to the wild-type transcript to help ensure effective and 
complete production of the mature form of recombinant bovine BMP15(Li, 
Rajanahally, et al., 2009). BMP15 is a member of the TGFβ super family of 
proteins and is first produced as a prepropeptide that must be enzymatically 
cleaved separating the proregion, containing the signal sequence, from the 
mature region, which contains the biologically active domain. To ensure efficient 
transcription of the exogenous gene, a Kozak consensus sequence was inserted 
5’ of the start ATG. In order to improve the detection and purification of the 
mature region, a detectable FLAG tag sequence (Asp-Tyr-Lys-Asp-Asp-Asp-
Asp-Lys) was inserted before the cleavage site. Further, the cleavage domain 
was modified for recognition by PACE/furin (Paired basic Amino acid Cleaving 
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Enzyme). This modification was made to ensure the efficient cleavage of the 
proprotein to form the mature peptide in vitro by a proprotein convertase 
endogenous to HEK-293 cells. 
This modified transcript was subcloned into the PCDNA 3 (Life 
Technologies) mammalian expression vector and transfected via electroporation 
into HEK-293 (human embryonic kidney 293) and FBK (fetal bovine kidney) cell 
lines. Following selection with geneticin (G418), an aminoglycoside antibiotic, 
cell lines were cultured at confluence for 48-72 hours before the culture medium 
was collected and filtered for purification. rbFL-BMP15 was purified from both 
cell lines using affinity chromatography with aseptic technique. Concentrations of 
the purified rbFL-BMP15 samples were then calculated based on densitometric 
measurements from Western blots using an anti-FLAG antibody.  
Materials and Methods 
RNA Isolation 
RNA was isolated from bovine ovarian tissue using an Rneasy kit 
(Qiagen), according to the manufacturer’s instructions, after thorough 
homogenization in buffer RLT. Following centrifugation, 70% ethanol was added 
to the lysate in order to allow RNA binding to the spin column. Contamination 
from genomic DNA was eliminated with an on-column Dnase I digestion for 15 
minutes at room temperature followed by several wash steps. The RNA was 
then collected with the addition of Rnase free water directly to the column and 
centrifugation to collect the eluate.  
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Reverse Transcription 
Complementary DNA (cDNA) was produced by reverse transcription with 
SuperScript II (Life Technologies) according to the manufacturer’s instructions. A 
12 µl reaction was first set up containing random primers, RNA, and dNTPs 
which was heated to a temperature of 65°C for 5 minutes before being placed 
on ice. First-strand buffer (5X) and dithiothreitol (DTT) were then added and the 
reaction was incubated at room temperature for 2 minutes before the addition of 
SuperScript II enzyme. The entire 20 µl reaction was incubated for 50 minutes at 
42°C followed by inactivation at 70°C for 15 minutes. 
FLAG Epitope Tag PCR 
A set of PCR directed mutagenesis reactions were designed to modify the 
wild type transcript in two segments (A&B) separated at the cleavage site. 
Segment A was amplified from 1 µg bovine ovarian cDNA using primers termed 
Kozak forward and cleavage reverse (Table 1) with AccuPrime™ Pfx DNA 
Polymerase (Life Technologies) in the following reaction conditions: 90°C for 2 
minutes; 30 cycles of 90°C for 30 seconds, 50°C for 30 seconds and 68°C for 1 
minute and 30 seconds; with a final extension of 68°C for 2 minutes. Segment B 
was amplified in similar fashion with FLAG forward and end reverse primers 
under the same reaction conditions. (Fig. 5) 
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Table 1 Primer sequences used for amplification and sequencing of rbFL-
BMP15. 
 
Name Sequence 
Kozak 
Forward TAATGAATTCGCCGCCACCATGGTCCTTCTGAGCATC 
Cleavage 
Reverse ATTACCCGGGGCCGCCGCTCAGGCTCCGCTTGCTCCGGTGGAGAAGAGAAGGGTCTTTTTC 
Flag 
Forward TAATCCCGGGGGAGACTACAAGGACGATGACGACAAGCAAGCAGGCAGTATTGCATC 
End 
Reverse ATTAGGATCCTCACCTGCATGTGCAGGA 
T7 TAATACGACTCACTATAGGG 
SP6 ATTTAGGTGACACTATAG 
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Figure 5 Diagram of rbFL-BMP15 PCR strategy. A) A set of PCR directed 
mutagenesis reactions were designed to modify the wild type transcript in two 
segments (A&B) separated at the cleavage site. Kozak forward and cleavage 
reverse primers (Table 1) were used for the amplification of segment A. B) FLAG 
forward and end reverse primers were used to amplify segment B. Segments 
were digested with XmaI restriction enzymes and ligated to form rbFL-BMP15 
(recombinant bovine FLAG-bone morphogenic protein 15) 
 
 
 
rbFL-BMP15 Assembly 
The products from PCR reactions for segments A and B were separated 
by electrophoresis in a 1% agarose in TAE (Tris-acetate-EDTA) gel containing 
ethidium bromide. Visualized bands were excised from the gel using a razor 
blade on an ultraviolet light box. Qiagen’s QIAquick gel extraction kit was used 
to collect purified PCR products from solubilized gel slices following the 
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manufacturer’s protocol. Concentration of the eluted DNA was ascertained using 
a NanoVue spectrophotometer (GE Healthcare). 500 ng DNA from segments A 
and B was digested in 50 µl with 10 units XmaI restriction enzyme (New England 
Biolabs) in the presence of BSA for 1 hour at 37°C. Restriction enzymes were 
removed using the QIAquick PCR Purification Kit (Qiagen). Digestion products 
were mixed with 5 volumes of buffer PB and centrifuged at 17,900 x g for 30 
seconds to bind DNA to independent columns. Following the addition of wash 
buffer and centrifugation, DNA was eluted with 30 µl of provided elution buffer. 
Segments A and B were ligated in a 20 µl reaction with the Rapid DNA 
Ligation kit (Roche). 4.5 µl of each segment’s eluate, the maximum volume for a 
20 µl reaction, was ligated for 5 minutes at 25°C before being placed on ice. 
Remaining enzyme was removed using a PCR purification kit reaction (Qiagen) 
to produce full-length rbFL-BMP15.  
Sub-cloning rbFL-BMP15 into PCDNA 3 
Full-length rbFL-BMP15 and PCDNA 3 (Life Technologies) were digested 
with EcoRI and XhoI restriction enzymes (NEB) in EcoRI buffer with BSA 
(bovine serum albumin) prior to ligation of the segments to produce the vector 
PCDNA rbFL-BMP15. 
The full-length rbFL-BM15 ligation product, 260 ng, was digested with 10 
units each of EcoRI and XhoI for 1 hour at 37°C and heat inactivated at 65°C for 
20 minutes before being cooled to 4°C. Approximately 1 µg of PCDNA 3 was 
restriction digested with 15 units each of EcoRI and XhoI under the same 
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conditions. Both products were mixed with loading dye and separated by 
electrophoresis in a 1% agarose in TAE gel containing ethidium bromide. The 
1.3 kb rbFL-BMP15 and 5.4 kb PCDNA 3 bands were excised with a razor blade 
and extracted with a QIAquick gel extraction kit and column according to the 
manufacturer’s instructions.  
 A ligation reaction was set up, using the Rapid DNA Ligation kit (Roche), 
for PCDNA rbFL-BMP15 in a 3:1 insert to vector molar ratio as follows: 2 µl 
PCDNA, 7 µl rbFL-BMP15 or water, 10 µl 2x buffer, 1 µl ligase. A control ligation 
to measure background was conducted by replacing the rbFL-BMP15 insert with 
7 µl water. Following a 5 minute incubation at 25°C, the product was placed on 
ice and introduced into 5-alpha competent E. coli (High Efficiency) from New 
England BioLabs using a standard transformation protocol. 
 A vial of 5-alpha competent E. coli were removed from -80°C and thawed 
on ice during the ligation reactions. 25 µl of E. coli was added directly to each 20 
µl ligation reaction mix and stored on ice for 30 minutes. The mixture was placed 
in a 42°C water bath for 1 minute and returned to the ice for 5 minutes before 
950 µl 2XYT was added and incubated at 37°C for 45 minutes on a shaking 
platform at 250 RPM. 500 µl of each broth was seeded onto a 10 cm petri dish 
containing 2XYT with 1.5% agarose and 50 µg/ml ampicillin and incubated 
overnight at 37°C.  
 Briefly, colonies were selected using a sterile 200 µl pipet tip, placed in a 
0.2 ml PCR tube containing 10 µl water and agitated before being removed. The 
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tubes were heated at 95°C for 10 minutes. A master mix containing 0.5 µM T7 
and SP6 sequencing primers, 0.2 µM dNTP mixture, 1x PCR buffer and taq 
DNA polymerase (Life Technologies) was added to a final volume of 20 µl. A 
PCR reaction to amplify the target region was run for 35 cycles using the 
following parameters: 95°C for 2 minutes; 30 cycles of 95°C for 30 seconds, 
55°C for 30 seconds and 72°C for 2 minutes, and final extension at 72°C for 7 
minutes. The PCR product was mixed with loading dye and separated in a 1% 
agarose in TAE gel to determine positive colonies. The colonies that were 
positive for the ~1.3 kb rbFL-BMP15 band were plucked from the agar plate and 
placed in 3 ml 2XYT broth containing 50 µg/ml ampicillin. The broth was grown 
overnight at 37°C on a rotating platform at 300 RPM. Prior to DNA collection with 
Qiaprep miniprep kit (Qiagen) a glycerol stock of the colony was prepared by 
mixing a small amount of the broth with 20% glycerol and storing the solution at -
80°C. 
 Bacteria were harvested by centrifugation at 6,800 xg for 3 minutes at 
25°C and lysed with alkaline buffer included with the Qiaprep miniprep kit. DNA 
from the lysate was then bound to a QIAprep spin column by centrifugation. 
Endonucleases and salts were removed by washing with buffer PB before DNA 
was collected with elution buffer heated to 60°C. 
Sequencing 
The sequence of PCDNA rbFL-BMP15 was verified from 5’ and 3’ 
directions using T7 and SP6 primers respectively. Plasmid DNA collected from 
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the minipreps was used as input for sequencing reactions as follows: 2 µl 
BigDye Terminator Ready Reaction Mix (Applied Biosystems), 1.7 µM primer T7 
or SP6, 300ng DNA, water to a final volume of 6 µl. Samples were placed in a 
thermal cycler and a program was run with the following conditions: 96°C for 2 
minutes; 30 cycles of 96°C for 15 seconds, 50°C for 15 seconds and 60°C for 4 
minutes, and a final step of 60°C for 5 minutes. Excess terminator dye and 
dNTPs were removed by centrifuging the sequencing product through a 
sephadex spin column hydrated with water (BioMax).  
Samples were sequenced by the DNA Technologies Core Lab (Texas 
A&M University) with 3130xl Genetic Analyzer (Applied Biosystems) and 
analyzed with Sequencher DNA Sequence Analysis software (Gene Codes 
Corporation). Overlapping sequences originating from T7 and Sp6 sites were 
analyzed and aligned with wild-type bovine BMP15 (NM_001031752.1).  
Transfection of HEK-293 and Fetal Bovine Kidney Cell Lines 
Human embryonic kidney 293 (HEK-293) and primary fetal bovine kidney 
(FBK) cells were cultured in T75 tissue culture flasks (BD Falcon) to 85% 
confluence at 37°C and 5% CO2 in Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12) with 10% fetal bovine serum (FBS) and 1X antibiotic-
antimycotic (Life Technologies). Cells were transfected using the Neon 
transfection system (Life Technologies) following the manufacturers guideline for 
preparation of adherent cells. HEK-293 or FBK cells (9*10^6) were suspended in 
600 µl provided resuspension buffer. For each cell line, 300 µl of cell suspension 
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was added to two 1.5 ml microcentrifuge tubes and 7.5 µg of PCDNA3 rbFL-
BMP15 or FL-GFP (Dr. Mike Golding) plasmid DNA was added. Cells were 
electroporated with one pulse of 1650 V for 20 ms and deposited into a 6-well 
plate (BD Falcon) containing equilibrated DMEM/F12 culture medium with 10% 
FBS and no antibiotics. At 24 hours post-transfection, the media was changed to 
DMEM/F12 with 10% FBS and 1X ABAM (DMEM/F12 complete). FL-GFP 
transfected cells were visualized for fluorescence and estimates of transfection 
efficiency were recorded at >50%.  
Cell Selection and Protein Expression 
At 90% confluence, cells transfected with rbFL-BMP15 were washed with 
2 ml PBS, incubated with 1 ml 1X trypsin (Gibco) for 5 minutes at 37°C and 
suspended in DMEM/F12 complete to a volume of 10 ml and moved into a T75 
tissue culture flask for expansion and selection. Following cell adherence, 0.3 
mg/ml geneticin (Gibco) was added for selection. At 90% confluency, media was 
aspirated from flasks, cells were washed with 10 ml PBS and incubated with 4 
ml 1X trypsin for 5 minutes at 37°C. Cells were suspended with the addition of 8 
ml DMEM/F12 complete. 4 ml of cell suspension was added to a T75 tissue 
culture flask containing 6 ml DMEM/F12 complete with 0.3 mg/ml geneticin. FBK 
rbFL-BMP15 and HEK rbFL-BMP15 cell lines were passaged under selection 
once more before protein collection began.  
FBK rbFL-BMP15 and HEK rbFL-BMP15 cell lines were allowed to reach 
confluence in DMEM/F12 complete with 0.3 mg/ml geneticin before the media 
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was changed to Opti-MEM reduced serum media (Life Technologies) containing 
2% FBS and 1X ABAM for 2-3 days of production. Media was removed with a 
serological pipette and filtered with 0.22 µm syringe filter (Tiffen) and Air-Tite 
syringe before addition of HALT protease inhibitor cocktail (Pierce). 
Purification of rbFL-BMP15 
Anti-FLAG M2 affinity gel (Sigma) was prepared according to the 
manufacturers’ instructions for FLAG Fusion Protein Immunoprecipitation. 100 µl 
anti-FLAG M2 affinity gel suspension was washed with the addition of 500 µl 
TBS (Tris-buffered saline) in a 1.5 ml microcentrifuge tube. The affinity gel was 
centrifuged for 30 seconds at 8,000 x g and the supernatant removed by 
pipetting. The pellet was suspended in 500 µl TBS before centrifugation and 
another wash with TBS. The resin was suspended in 500 µl TBS and incubated 
overnight on a tube rotator with 10 ml cell-conditioned and filtered Opti-MEM 
media containing protease inhibitor. The affinity resin was pelleted by 
centrifugation at 4,000 x g for 45 seconds and moved to a clean 1.5 ml 
microcentrifuge tube. The resin pellet was suspended in 500 µl TBS and 
centrifuged at 8,000 x g for 30 seconds three times. rbFL-BMP15 was eluted by 
incubation with 100 µl TBS 1% BSA + 200 ng/µl 3X FLAG peptide (Sigma) for 
45 minutes at room. The resin was pelleted by centrifugation at 8,000 x g for 30 
seconds and the supernatant containing rbFL-BMP15 was removed and stored 
at -80°C. 
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Anti-FLAG Western blot 
Concentration of the purified rbFL-BMP15 was calculated using 
densitometric measurements in comparison to a standard curve of amino 
terminal FLAG-E. coli bacterial alkaline phosphatase (BAP) standards (Sigma). 
15 µl purified rbFL-BMP15 was mixed with 15 µl 2X Laemmli buffer (Bio-Rad) 
containing 2M Focus DTT (G Biosciences) and heated for 5 minutes at 95°C. 
FLAG-BAP standards of 200, 100, 50 and 25 ng were diluted in a total volume of 
10 µl TBS and mixed with an equal volume of 2X Laemmli buffer containing 2M 
DTT and heated for 5 minutes at 95°C. The complete sample and 20 µl of each 
standard was loaded into 4-20% or 15% Mini-PROTEAN TGX precast 
polyacrylamide gels (Bio-Rad) in chilled Tris/glycine/SDS buffer (25 mM Tris, 
192 mM glycine, 0.1% sodium dodecyl sulfate). Electrophoresis was conducted 
at 110 V for 45 minutes until the dye front was within 2 cm of the bottom of the 
gel cassette. Proteins were transferred to Polyvinylidene fluoride (PVDF) 
membrane (Amresco), pre-soaked in methanol, at 100 V for 48 minutes in ice 
cold Towbin’s transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol). 
The membrane was blocked at 37°C for 1 hour with TBS + 0.1% 
Tween20 + 5% non-fat dry milk and 20 µl/ml goat serum on a rocking platform. 
Monoclonal mouse anti-FLAG M2 antibody (Sigma) was diluted in fresh blocking 
buffer at 1:1000 and incubated with the membrane overnight at 4°C on a rocking 
platform. Excess wash buffer (TBS + 0.1% Tween20) was added to the 
membrane and incubated for 15 minutes at 25°C. The wash step was completed 
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3 times. Goat anti-Mouse IgG HRP (Jackson ImmunoResearch Laboratories) 
was diluted 1:20,000 in TBS and incubated with the membrane for 1 hour at 
25°C. Three 15 minute washes with excess wash buffer were completed at 25°C 
after the secondary antibody dilution was decanted. 2 ml of pre-mixed 
ChemiGlow substrate (Protein Simple) was added to the blot and allowed to 
incubate for 3 minutes before being imaged on the FlourChem E (Protein 
Simple) camera dock. 
Image analysis was conducted using AlphaView Stand Alone software 
(Protein Simple) with lane profile densitometry. A standard curve was created 
using the measurements from the FL-BAP samples and the unknown 
concentrations were fit to the curve to determine the amount of rbFL-BMP15 
present at 17 kDa. 
Results 
The Matzuk laboratory at Baylor College of medicine reported success 
with modification and production of recombinant human BMP15 (Li et al. 2009). 
For efficient translation, a Kozak sequence was added to the beginning of the 
transcript (Kozak, 1987; Kozak, 1986). The cleavage site was modified to match 
the von Willebrand factor (vWF) cleavage site, which is efficiently processed by 
PACE/furin. HEK-293 cells highly express the proprotein convertase PACE/furin 
making it a logical selection. A FLAG epitope sequence was added 3’ of the 
cleavage site and 5’ to the mature region of the sequence for purification and 
identification by Western blotting. We produced, with these modifications, an 
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expression vector capable of being processed efficiently in vitro, secreted into 
the supernatant and containing a FLAG sequence at the N-terminus of the 
mature peptide. Once cell lines were established, the supernatant could be 
collected from cultured cells and purified using FLAG affinity gel for downstream 
testing. 
A PCR strategy was designed based on the modifications of the transcript 
at the N-terminus end, cleavage site and C-terminus. Two segments, named A 
and B, were amplified in separate reactions from bovine ovarian cDNA. We 
designed primers based on the wild type sequence of bovine BMP15 with 
modification to the cleavage site and the addition of specific restriction enzyme 
sites as well as a Kozak consensus sequence. Following amplification of the 
fragments, products were ligated after a restriction digest with Xma1 to form full-
length rbFL-BMP15. (Fig. 6) 
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Figure 6 Representation of rbFL-BMP15 as modified from the wild type gene. A 
Kozak consensus sequence was added for efficient production in vitro. The 
native cleavage site was modified to match the vWF site cleaved by PACE/furin 
which is abundantly expressed by HEK-293 cells. A FLAG epitope tag was 
added downstream of the cleavage site for purification by FLAG affinity gel and 
detection by anti-FLAG Western blotting. 
 
 
 
For expression in mammalian cell lines, rbFL-BMP15 was inserted into 
the multiple cloning site of PCDNA 3 designed with the human cytomegalovirus 
immediate-early (CMV) promoter for high expression in mammalian cells. 
Sequence analysis revealed the rbFL-BMP15 clone 1 had the correct and in-
frame sequence and was used for all downstream applications. HEK-293 and 
FBK cell lines were transfected by electroporation using the Neon system. Cell 
lines were exposed to geneticin during culture to select for cells that expressed 
neomycin resistance afforded by the PDCNA rbFL-BMP15 plasmid. (Fig. 7) 
Conditioned medium from the transfected cell lines was incubated with 
FLAG affinity gel to collect the FL-BMP15 protein and eluted by competitive 
binding with a 3X FLAG peptide. The concentration of the purified product was 
obtained by densitometric analysis of a chemiluminescent Western blot as 
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compared to a standard curve of FLAG-BAP for each collection. (Fig. 9) The 
final concentration of purified rbFL-BMP15 (final volume of 100 µl per collection) 
varied by collection and cell type. Eluate from HEK-293 rbFL-BMP15 cells was 
consistently higher in concentration (10-15 ng/µl) but interestingly produced 2 
distinct immunoreactive bands. rbFL-BMP15 collected from the FBK cell line 
averaged 5-10 ng/µl and only produced the higher of the bands from the HEK 
cell line. (Fig. 8) 
 
 
 
Figure 7 PCDNA rbFL-BMP15 vector map. rbFL-BMP15 was inserted at the 
multiple cloning site and downstream of the human CMV promoter of PCDNA 3 
mammalian expression vector. Locations of T7 and SP6 sites used for 
sequencing are shown. SV40 promoter drives neomycin resistance upstream of 
the SV40 origin of replication for selection of eukaryotic cells containing the 
plasmid with geneticin (G418) 
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Figure 8 Purified rbFL-BMP15 from HEK-293 and MDBK cell lines. Anti-FLAG 
Western blot with immunoreactive bands for rbFL-BMP15 from HEK-293 (Lane 
1) and FBK (Lane 2) transfected cell lines. Conditioned media was purified using 
FLAG-affinity gel and eluted with 3X-FLAG peptide in TBS + 1% BSA. FLAG-
BAP standards of 50, 100 and 200 ng (Lanes 4-6) were used to create a 
standard curve for calculation rbFL-BMP15 concentration. 
 
 
 
 
 
Figure 9 FLAG-BAP Standard curve used to calculate rbFL-BMP15 
concentration. Standard curve was produced based on chemiluminescent signal 
from 50, 100 and 200 ng FLAG-BAP standards.  
 
   Lane       1           2           3            4             5           6 
49 kDa 
17 kDa 
15 kDa 
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Discussion 
Development of a reliable method for production of a large quantity of 
highly purified recombinant protein was an essential step in testing our 
hypothesis. Several methods of protein purification are available including size 
exclusion chromatography and immunoprecipitation. Due to the high specificity 
of immunoprecipitation, we chose to produce recombinant bovine BMP15 with a 
FLAG tag. The FLAG purification system from Sigma has the advantage of 
elution without denaturing conditions with a 3X FLAG peptide based on the 
principle of competitive binding.  
BMP15, like other members of the TGFβ family, is first produced as a 
prepropeptide then enzymatically cleaved to resulting in a pro-region and a 
mature functional protein. Based on this process, there are only two options for 
the placement of the affinity tag on the final product. The tag could be placed at 
the C-terminus of the mature region of the sequence, but TGFβ proteins have a 
conserved cysteine knot structure at the C-terminal end. The addition of a 
hydrophilic tag could have disrupted this structure and prevented proper 
dimerization. The other option for a tag is placement 3’ of the cleavage site so 
the tag will be located on the N-terminal end of the mature peptide after 
processing. Based on previous reports, we chose placement at 3’ of the 
cleavage site (Li, et al. 2009). In addition to purification, protein identity should 
be verified by Western blotting. This process requires an antibody specific to the 
protein of interest. There are currently no commercially available antibodies for 
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bovine BMP15. Monoclonal FLAG antibodies are, however, commercially 
available and exhibit high specificity. For these reasons combined with the need 
to purify the mature recombinant protein, we chose to use the FLAG system. 
The Matzuk laboratory at Baylor College of medicine reported success 
with modification and production of recombinant human BMP15 (Li et al. 2009). 
For efficient translation, a Kozak sequence was added to the beginning of the 
transcript (Kozak, 1986). The cleavage site was modified to match the von 
Wildebrand factor (vWF), which is efficiently processed by PACE/furin, based on 
the efficiency of cleavage in vitro. Finally, a FLAG sequence was added 3’ of the 
cleavage site and 5’ to the mature region of the sequence. In this manner, we 
produced a protein transcript capable of being processed in vitro, secreted into 
the extracellular supernatant and containing a FLAG tag at the N-terminus of the 
mature peptide. Once cell lines were established, the supernatant could be 
collected from cultured cells and purified with FLAG affinity gel for downstream 
testing.  
In order to produce a stable cell line, we first attempted transduction with 
a retroviral construct. The rbFL-BMP15 transcript was inserted into the multiple 
cloning site of the mammalian retroviral expression vector MSCV-PIG (Puro 
IRES GFP) and combined with VSVG (Vesicular Stomatitis Virus glycoprotein 
envelope) and PSI retroviral packaging element plasmids for viral production. 
Collection of recombinant protein from these cell lines proved very difficult 
despite the presence of GFP labeled cells, which indicated successful 
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transduction. Analysis of genomic DNA and mRNA from the transduced cell line 
revealed the presence of the rbFL-BMP15 transgene in the genomic DNA but 
not in mRNA despite the presence of GFP mRNA, suggesting that rbFL-BMP15 
was not being transcribed. The lack of gene transcription could have been due 
to low expression of the phosphoglycerate kinase promoter utilized in the 
MSCV-PIG vector by the cell lines. Following several attempts at protein 
collection, a new strategy was devised using transfection and selection. 
Based on previous results, rbFL-BMP15 was then cloned into PCDNA 3, 
a vector designed for high expression in mammalian hosts with the human 
cytomegalovirus immediate-early (CMV) promoter. Given the difficulty of 
transfecting primary cell lines, we chose to use the Neon transfection system 
from Life Technologies. The FL-GFP control transfected cells were estimated at 
50-60% GFP positive 48 hours after electroporation.  Following 2-3 days of 
culture, media was removed from PCDNA rbFL-BMP15 cells lines and tested. 
This process allowed us to determine the concentration of each collection of 
recombinant protein for accurate addition to in vitro maturation media. We were 
able to repeatedly collect protein at a eluate concentration of 5-10 ng/µl, which 
allowed us to easily add rbFL-BMP15 at a final concentration of 100 ng/ml for in 
vitro maturation testing. It was noted, however, that the total amount of 
recombinant protein recovered from the bovine FBK cell line was uniformly lower 
than that collected from the human HEK-293 cell line. We postulate that this 
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difference is attributable to the difference in activity of the human CMV promoter 
driving the transcription of rbFL-BMP15 in the PCDNA 3 vector backbone.  
We have developed here two stable cell lines, human and bovine, 
producing recombinant bovine FLAG tagged bone morphogenic protein 15, 
allowing us to compare the protein production from the cell lines without the 
variable of individual transfection efficiency and characterize the products from 
each cell line. In order to understand the differential production of protein from 
an identical vector by human and bovine cell lines, recombinant proteins were 
next characterized and analyzed for bioactivity. 
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CHAPTER III 
CHARACTERIZATION AND FUNCTIONAL ANALYSIS OF RECOMBINANT 
BOVINE FLAG-BONE MORPHOGENIC PROTEIN 15 
 
Introduction 
The objective of the following experiments was to design and test several 
in vitro assays in order to characterize rbFL-BMP15 produced by HEK-293 and 
FBK cell lines and test bioactivity based on the observed differences in 
molecular weight of the protein produced by each cell line. These experiments 
were essential to understanding the differential processing of an identical 
expression vector by human and bovine cell lines. Matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) analysis was utilized to collect 
accurate molecular mass and charge of rbFL-BMP15 from both cell lines. The 
human HEK-293 products were of great interest because unlike the bovine FBK 
cell line, HEK-293 cells produced 2 distinct species of protein by Western blot 
analysis. BMP15 signals through a BMP receptor type II and (ALK6) TGFBR1 
(transforming growth factor, beta receptor 1) heteromeric complex, transducing 
the signal the interior of the cell by phosphorylation of the receptor SMAD 1/5/8 
(mothers against decapentaplegic homolog 1/5/8), a transcription factor 
(Anderson & Darshan, 2008). We tested the ability of the recombinant proteins 
to bind to the receptor complex and successfully induce the phosphorylation of 
SMAD 1/5/8 by immunoreactivity to an antibody for SMAD 1/5 phosphorylated at 
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serine residues 463 and 465. Receptor binding specificity was determined using 
dorsomorphin, a selective inhibitor of BMP signaling. Dorsomorphin is an ATP-
competitive inhibitor of AMPK (AMP-activated protein kinase) that blocks that 
action of the tyrosine kinase receptor to phosphorylate receptor SMADs. Primers 
were then designed for genes known to be upregulated by the action of BMP15: 
HAS2 (hyaluronan synthase 2), PTX3 (pentraxin 3), TSG6 (tumor necrosis factor, 
alpha-induced protein 6) and PTGS2 (prostaglandin-endoperoxide synthase 2). 
Finally, quantitative real time PCR analysis was conducted on groups of 
cumulus oocyte complexes following in vitro maturation with medium containing 
rhBMP15, homologous (FBK) rbFL-BMP15 or heterologous (HEK-293) rbFL-
BMP15.  
Materials and Methods 
MALDI-TOF (Matrix-assisted laser desorption/ionization-time of flight) 
 Conditioned medium from HEK-293 and FBK rbFL-BMP15 cell lines was 
purified using anti-FLAG M2 affinity gel (Sigma) as described previously without 
the addition of BSA to the elution buffer. 100 µl of purified sample in TBS from 
each cell line was SpeedVac (Thermo Scientific) concentrated to approximately 
10 µl. Acidification of the samples was conducted by the addition of 1/10 volume 
of 1% trifluoroacetic acid (TFA) (0.1% final concentration). Samples were solid 
phase extracted with a C4 ZipTip (Millipore) and spotted with alpha-cyano-4-
hydroxycinnamic acid as a matrix (6 mg/ml in 50% acetonitrile, 0.1% TFA). Mass 
analysis was performed using a Shimadzu/Kratos Axima CFR MALDI-TOF mass 
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spectrometer in linear mode with accelerating voltage of 20,000, pulse extraction 
voltage of 2,000 and linear detector voltage of 2,950. Spectra were collected 
with a minimum of fifty laser shots with a mass accuracy at ~0.1%. The analysis 
was externally calibrated using Cytochrome C. 
Phosphorylated-SMAD 1/5 Western Blot 
 HeLa cells were cultured in 6 well plates (BD Falcon) at 37°C and 5% 
CO2 in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) 
with 10% fetal bovine serum (FBS), 50 units/ml penicillin and 50 µg/ml 
streptomycin (Life Technologies). Media was changed to OPTIMEM with 2% 
FBS, 50 units/ml penicillin and 50 µg/ml streptomycin at 80% confluence for 3 
hours prior to treatment. Media was removed and wells were washed with PBS 
before the addition of 100 ng/ml rhBMP15 (recombinant human BMP15, R&D 
Systems), HEK-293 rbFL-BMP15 conditioned medium or HEK-293 wild type 
conditioned medium. Conditioned media was collected from confluent cells 
cultured for 2 or 3 days with OPTIMEM with 2% FBS, 50 units/ml penicillin and 
50 µg/ml streptomycin. Media was centrifuged at 20,000 x g for 10 minutes at 
4ºC to pellet cellular debris and stored in 1 ml aliquots at -80ºC.  
Following 1 hour of incubation at 37ºC and 5% CO2 with conditioned 
medium containing rbFL-BMP15, HeLa cells were washed twice with PBS 
collected for nuclear extraction. 1 ml of buffer A (10 mM HEPES, pH 7.5; 10 mM 
KCl; 0.1 mM EDTA) was prepared by the addition of 25 µl 10% IGEPAL CA-630 
(Sigma-Aldrich), 1 µl 2M Focus DTT (G Biosciences) and 10 µl 100X HALT 
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protease/phosphatase inhibitor (Thermo Scientific). 200 µl was added to each 
well of treated HeLa cells and the plate was rocked at room temperature for 10 
minutes. Cells were scraped with a pipet tip bent at a 90º angle, transferred to a 
1.5 ml microcentrifuge tube and centrifuged at 20,000 x g for 3 minutes at 4ºC. 
Tubes were immediately placed on ice and the cellular lysate removed in the 
supernatant. 0.5 ml buffer B (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 10% 
glycerol) was prepared by the addition of 5 µl 100X HALT protease/phosphatase 
and 0.5 µl 2M Focus DTT. 30 µl of prepared buffer B was added to each pellet 
and shaken at 1,000 RPM in an Eppendorf thermomixer at 4ºC for 2 hours. The 
lysates were centrifuged for 5 minutes at 20,000 x g for 5 minutes and the 
supernatant collected as nuclear lysate.  
Protein content of the nuclear extracts was determined by a Bradford 
assay. 5 standards were prepared within the range of 100 to 1000 µg/ml BSA 
and mixed with 1X Bradford Reagent (BioRad) before measurement of 
absorbance at 595 nm with a GE NanoVue spectrophotometer. 2.5 µl of each 
nuclear extract was mixed with 1X Bradford reagent, absorbance was measured 
and the concentration was determined by its placement on the standard curve.  
Nuclear extract from HeLa cells (2 µg) treated with 100 ng/ml rhBMP15, 
conditioned medium containing rbFL-BMP15 or control conditioned medium was 
mixed with an equal volume 2X Laemmli buffer (Bio-Rad) containing 2M DTT 
(focus) and heated for 5 minutes at 95°C. The complete sample was loaded into 
a 10% Mini-PROTEAN TGX precast polyacrylamide gels (Bio-Rad) in chilled 
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Tris/glycine/SDS buffer (25 mM Tris, 192 mM glycine, 0.1% sodium dodecyl 
sulfate). Electrophoresis was conducted at 200 V for 40 minutes until the dye 
front was within 2 cm of the bottom of the gel cassette. Proteins were transferred 
to PVDF (Polyvinylidene fluoride) membrane (Amresco), pre-soaked in methanol, 
at 100 V for 60 minutes in ice cold Towbin’s transfer buffer (25 mM Tris, 192 mM 
glycine, 20% (v/v) methanol).  
The membrane was blocked at 25°C for 1 hour with TBS + 0.1% 
Tween20 + 5% non-fat dry milk and 20 µl/ml goat serum on a rocking platform. 
Monoclonal rabbit Phospho-Smad1/5 (Ser463/465) antibody (Cell Signaling 
Technology) was diluted in TBS, 0.1% Tween20, 5% w/v BSA at 1:1,000 and 
incubated with the membrane overnight at 4°C on a rocking platform. Excess 
wash buffer (TBS + 0.1% Tween20) was added to the membrane and incubated 
for 15 minutes at 25°C. The wash step was completed 3 times. Mouse anti-
Rabbit IgG HRP (Jackson ImmunoResearch Laboratories) was diluted 1:5,000 
in TBS and incubated with the membrane for 1 hour at 25°C. Three 15 minute 
washes with excess wash buffer were completed at 25°C after the secondary 
antibody dilution was decanted. 2 ml of pre-mixed SuperSignal West Pico 
chemiluminescent substrate (Thermo Scientific) was added to the blot and 
allowed to incubate for 3 minutes before being imaged on the AlphaFlour (Alpha 
Innotech) camera dock. 
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BMPRI (Bone Morphogenic Protein Receptor I) Inhibition 
 HeLa cells were cultured in 6-well plates (BD Falcon) with DMEM F/12 
complete in 5% CO2 at 37ºC to 80% confluence. Dorsomorphin (Sigma Aldrich) 
is a selective BMP inhibitor and acts as an ATP-competitive inhibitor of AMPK. 
Dorsomorphin was added to HeLa cells for 1 hour at a final concentration of 4 
µM. Cells were left untreated, or 100 ng/ml rhBMP15, rbFL-BMP15 from HEK-
293 or FBK cell lines was added for 1 hour to cells treated with dorsomorphin or 
untreated. Nuclear lysates were collected for phosphorylated SMAD 1/5 Western 
blotting as previously described. 
In Vitro Maturation 
 In vitro maturation medium was prepared by adding 10% FBS, 50 units/ml 
penicillin and 50 µg/ml streptomycin to M199 Earl’s salts buffered with sodium 
bicarbonate (Gibco). rhBMP15, rbFL-BMP15 from HEK-293 or FBK cell lines 
was added at a final concentration of 100 ng/ml to the medium before overnight 
shipment to TransOva (Long Prarie, MN) at 4°C. Control medium was sent 
without addition of recombinant protein. Upon arrival, the medium was 
equilibrated to 5% CO2 at 37ºC. bFSH and bLH (bovine follicle stimulating 
hormone, bovine luteinizing hormone) was added by TransOva according to 
protocol. Cumulus-oocyte complexes were aspirated from abattoir derived 
ovaries and shipped overnight to the Reproductive Sciences Complex with a 
portable incubator containing tubes with approximately 1.5 ml of each media and 
50 oocytes/tube (treatment). Tubes were uncapped and placed in a 5% CO2 and 
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37.5ºC incubator when the shipment arrived to ensure proper buffering until a 
maturation time of 24 hours was reached. Three separate rounds of in vitro 
maturation were completed as individual biological replicates. 
RNA Collections 
Groups of approximately 50 cumulus oocyte complexes were lysed in 350 
µl buffer RLT (Rneasy kit (Qiagen)) and vortexed for 2 minutes to homogenize 
the sample. The lysate was loaded onto a QIAshredder spin column (Qiagen) 
and centrifuged at 20,000 x g for 2 minutes. The flow-through was collected, 350 
µl of 70% ethanol was added and the sample mixed by pipetting and loaded 
onto a Qiagen Rneasy spin column. RNA was bound to the column by 
centrifugation at 8,000 x g for 15 seconds. The column was washed with 350 µl 
RW1 before on-column Dnase treatment. 10 µl Dnase I (Qiagen) was mixed with 
70 µl buffer RDD for each reaction. 80 µl was added to the membrane of each 
column and incubated for 15 minutes at room temperature. 350 µl buffer RW1 
was added to the column and centrifuged at 8,000 x g for 15 seconds. Two wash 
steps with 500 µl buffer RPE were completed before 30 µl Rnase-free water was 
added directly to the membrane for elution at 8,000 x g for 1 minute. 
Reverse Transcription 
 RNA, 100 ng, as measured by a GE NanoVue spectrophotometer, was 
used as the input for a reverse transcription using the Q-Script cDNA supermix 
(Quata Biosciences). 4 µl Q-Script cDNA supermix (5X) was mixed with 100 ng 
RNA and water to a total volume of 20 µl and incubated under the following 
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reaction conditions: 25ºC for 5 minutes, 42ºC for 30 minutes, 85ºC for 5 minutes 
and 4ºC hold. No reverse transcription (no-RT) control reactions were set up 
with the 5X supermix replaced with water and incubated using the same 
program. 
Primer Design 
 Primers were designed and tested for HAS2, PTX3, TSG6 and PTGS2 
using published sequences from NCBI with assistance from Primer3 Plus 
(http://www.bioinformatics.nl) and NetPrimer (Premier Biosoft). An optimum 
primer was described as 18-22 nt in length, Tm of 60ºC, a minimum of secondary 
structure or dimerization, GC content of 50%, and a product of 100-200 bp 
spanning an intron boundary. Oligonucleotides were synthesized by Life 
Technologies and reconstituted from lyophilized pellets at 100 nM with molecular 
grade water. Working stocks of primers were prepared by dilution 1:10 to a 10 
nM concentration. 
Primer Testing 
RNA was collected from cumulus cells post-fertilization and reverse 
transcribed with previously described methods. Standard curves of cDNA 
dilutions were prepared for testing the linear response of primer pairs at 1:10 (2 
ng cDNA/reaction), 1:50 (0.4 ng), 1:250 (80 pg), 1:1250 (16 pg), and 1:6250 (3.2 
pg). Reactions were set up in triplicate as follows: 6 µl DyNAmo Flash SYBR 
green mastermix (Finnzyme), 0.25 µl 50X ROX reference dye, 0.2 µl (0.2 nM 
final concentration each) primers, 2 µl H2O, and 4 µl cumulus cell cDNA. 
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Samples were run on a StepOnePlus Real-Time PCR machine (Applied 
Biosystems) under the following reaction conditions: 95ºC for 5 minutes; 40 
cycles of 95ºC for 30 seconds, 58ºC for seconds and 72ºC for 1 minute; followed 
by a melt curve analysis. Standard curves were generated and R2 values 
calculated by StepOne software (Applied Biosytems). 
Quantitative Real-Time PCR 
 cDNA and no-RT reactions from treated cumulus oocyte complexes were 
diluted at 1:50 for a final concentration of 0.4 ng cDNA per qPCR reaction. 
Reactions were set up as described for primer testing with no-RT sample, water 
or triplicates of cDNA from each treatment. Samples were run on a CFX384 
Touch Real-Time machine (BioRad). Expression of target genes was normalized 
to the mean of GAPDH and YWHAZ Cq using the ΔΔCT method with CFX 
software (BioRad). At least two technical replicates were completed for each of 
the three biological replicates. 
Statistical Analysis 
 Statistical analysis of gene expression was performed with JMP 9 (SAS 
Institute). Expression, as calculated by the CFX manager software with GAPDH 
and YWHAZ as reference genes and normalized to the untreated control for 
each replicate, was tested for statistically significant differences in treatment and 
within the gene by ANOVA (analysis of variance). If p<0.05 for the ANOVA test, 
a Wilcoxon/Kruskal Wallis nonparametric test was used to verify rejection of the 
null hypothesis (H0= µ1=µ2=µ3=µ4). Control expression values were excluded for 
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a Brown Forsythe test for unequal variances with p>0.05. The assumption of 
normality was checked by plotting the distribution of residual values, testing for 
Goodness of Fit with p>0.05 and checking for a linear pattern on the Normal 
Q/Q plot. Within each gene, every pair of expression values was compared with 
a Tukey/Kramer HSD test and a Dunnett’s test with control was used to assess 
a statistical difference between a treatment and the control with a p<0.05 
threshold for significance.  
Results 
Western blots of purified samples matched a previous report of two 
distinct immunoreacitve bands of recombinant human BMP15 at approximately 
15 and 17 kDa from HEK-293 cells (Fig. 8) (Li, Rajanahally, et al., 2009). Mature 
rbFL-BMP15 was predicted to be 15.5 kDa based on amino acid sequence. 
Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) analysis 
can give mass accuracies better than 0.1 kDa and was used to collect accurate 
molecular weights of the protein; in particular to ensure the lower 15 kDa band 
was not a degraded product. Samples are ionized by laser pulses and separated 
by a mass to charge ratio and plotted versus absolute intensity to generate a 
spectrum. MALDI-TOF analysis resulted in multiple mass/charge peaks 
corresponding to the two masses of 15.5 and 17.1 kDa from the HEK-293 cell 
line and a single peak corresponding to 17.1 kDa from the FBK cell line. (Fig. 
10) The results were reported as mass over charge and therefore the mass has 
to be interpreted based on a number of charges. A total of four major peaks 
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were noted with two unique to the HEK-293 cell line matching the 15.5 kDa 
immunoreactive band. These results suggest that the 17.1 kDa protein from the 
FBK cell line is a result of post-translationally added side chains, likely N-
glycosylated, that exist in multiple charge forms and that the 15.5 kDa protein is 
unmodified and not a degraded product. 
Nuclear lysates collected from HeLa cells following exposure to 
recombinant human BMP15 or rbFL-BMP15 from HEK-293 conditioned medium 
showed an increase in phosphorylated SMAD 1/5 over the untreated group by 
Western blot with recombinant hBMP15 demonstrating the highest activity. (Fig. 
11) This increase demonstrates that rbFL-BMP15 is capable of binding to BMP 
receptor type II and inducing the SMAD signaling pathway and is therefore 
biologically active. 
 
  
  
	  
55	  
Figure 10 Matrix-assisted laser desorption/ionization-time of flight MALDI-TOF 
analysis to determine accurate mass/charge ratio of purified samples from FBK 
and HEK-293 cell lines transfected with PCDNA rbFL-BMP15. (Figures A and B 
represent a continuation of the same spectrum starting from a m/z value of 
2,500 in A and continuing from 5,000 to 16,000 in B) Ovals mark charged 
species of a 15.4 kDa protein and squares mark multiple charged a 17.1 kDa 
protein, likely N-glycosylated. A) FBK (top) and HEK-203 (bottom) peaks 
measuring m/z 2.86 representing a 6 charged protein of 17.1 kDa. B) 
Continuation of A) at larger m/z values. Peaks at 15.47 and 7.74 kDa in the 
HEK-293 sample correspond to the 15 kDa rbFL-BMP15 with 1 and 2 positive 
charges, respectively. The 5.7 peak represents a 17.1 kDa protein with 3 
positive charges. This figure reveals a difference in the final protein produced by 
bovine and human cell lines from the same vector.  
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Figure 11 Phosphorylated SMAD 1/5 Western blot from nuclear lysates of 
treated HeLa cells. Cells were treated for 1 hour with 100 ng/ml rhBMP15 
(recombinant human BMP15, R&D Systems), HEK-293 rbFL-BMP15 
conditioned medium or HEK-293 wild type conditioned medium. Lane 1: Magic 
Mark XP (Life Technologies); Lane 2: 100 ng/ml rhBMP15; Lane 3: HEK-293 
rbFL-BMP15 conditioned medium; Lane 4: HEK-293 wild type conditioned 
medium. 
 
 
 
 Treatment with dorsomorphin, a selective BMP signaling inhibitor, 
decreased the phosphorylation of SMAD 1/5 in HeLa cells after treatment with 
recombinant hBMP15 or rbFL-BMP15 from HEK-293 and FBK cell lines. (Fig 12) 
Importantly, this result shows specific action of rbFL-BMP15 from both cell lines 
through the classical BMP and TGFBR1 receptor heterodimer and signal 
transduction by activation (phosphorylation) of SMAD transcription factors. 
Nuclear lysates from wild-type HeLa cells or treated with dorsomorphin at 4 µM 
60 kDa 
 Lane         1           2            3           4 
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were collected following exposure to 100 ng/ml hBMP15, rbFL-BMP15 from 
HEK-203 and FBK cell lines, or TBS + 1% BSA as a vehicle control for the 
purified proteins. Densotometric measurements corrected locally for background 
were compared and showed a marked decrease in the amount of 
immunoreactive phosphorylated SMAD 1/5. (Table 2, Fig. 13) For example, the 
background corrected average for hBMP15 treatment was decreased by 80% 
and rbFL-BMP15 from HEK cells was decreased by 47% following dorsomorphin 
administration. FBK derived rbFL-BMP15 and the untreated group had 
undetectable levels of phosphorylated SMAD 1/5 after exposure to 
dorsomorphin. 
 
 
 
Figure 12 Phosphorylated SMAD 1/5 Western blot from nuclear lysates of 
treated HeLa cells with or without Dorsophomorphin BMP receptor inhibitor. 
HeLa cells were treated for 1 hour at a final concentration of 4 µM. Cells were 
left untreated, or incubated 100 ng/ml of rhBMP15, rbFL-BMP15 from HEK-293 
or FBK cell lines before nuclear extraction. Lane 1: Precision Plus Dual Color 
(BioRad); Lanes 3-6 treated with dorsomorphin. Lane 3: rhBMP15; Lane 4: HEK-
293 rbFL-BMP15; Lane 5: FBK rbFL-BMP15; Lane 6: TBS + 1% BSA vehicle 
control Lanes 7-10: same treatments as lanes 3-6 without dorsomorphin. 
 
 
 
Lane 1    2     3      4     5      6      7      8     9    10 
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Table 2 Densitometry analysis from phosphorylated SMAD 1/5 Western blot of 
HeLa nuclear lysate following dorsomorphin treatment. Background corrected 
averages were normalized to untreated cells exposed to TBS + 1% BSA as a 
control. Dorsomorphin values represent a percentage of expression as 
compared to its untreated counterpart. 
 
Treatment No Inhibitor Dorsomorphin (4 µM) 
hBMP15 3.07 0.20 
HEK-293 rbFL-BMP15 1.82 0.53 
FBK rbFL-BMP15 1.26 0.00 
Control 1.00 0.00 
 
 
 
 
Figure 13 Phosphorylated SMAD 1/5 levels following dorsomorphin treatment. 
HeLa cells were left untreated or treated with 4 µM dorsomorphin, a selective 
BMP signaling inhibitor, for 1 hour. Cells were then exposed to 100 ng/ml 
hBMP15, rbFL-BMP15 from HEK-293 or HEK cells, or TBS + 1% BSA as a 
vehicle control. Untreated values are background corrected averages relative to 
control treatment. Dorsomorphin treatment values represent levels of 
phosphorylated SMAD 1/5 as compared to untreated levels in the same group. 
hBMP15 stimulation was decreased 80%, HEK-293 decreased by 47% and FBK 
and Control groups had undetectable levels after treatment with dorsomorphin 
inhibitor demonstrating that rbFL-BMP15 signals through the canonical BMP 
signaling pathway. 
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 Multiple primer pairs were designed and tested for four BMP15 stimulated 
genes: PTX3, HAS2, PTGS2 and TSG6 (Bos taurus). (Table 3) Standard curves 
created by increasing dilutions of template cDNA. Primer sets were chosen 
based on linearity of standard curves (R2 > 0.99) and calculated primer 
efficiency. (Fig. 14) Standard curves using bovine cumulus cell cDNA template 
for the chosen primer pair for each gene are shown along with their sequences. 
 
 
 
Table 3 Real-time quantitative PCR primer sequences for BMP15 stimulated 
genes. GAPDH and SDHA primers were used for reference genes. 
 
Name Forward Reverse 
PTX3 GTTTTGTGCGCTCTGGTCTGC GGTGAAGAGCTTGTCCCACTCG 
HAS2 ATCCCATGGTTGGAGGTGTCGG AGGTCCGCTAATGCACTGGACAC 
TSG6 GTCTCAATAGAAGTGAAAGATGGG GCAGTCACTGAAGCATCACTTAGG 
PTGS2 TCCTGTGCCTGATGACTGCC TTGATGGGTGAAGTGCTGGG 
GAPDH CTGCCCGTTCGACAGATAG CTCCGACCTTCACCATCTTG 
SDHA ACCTGATGCTTTGTGCTCTG TCGTACTCGTCAACCCTCTC 
 
 
  
	  
61	  
 
 
Figure 14 Standard Curves of cDNA dilutions by qPCR for BMP15 stimulated 
genes. Standard curves of primer sets for PTX3, HAS2, PTGS2 and TSG6 
showing a linear response with dilutions of bovine cumulus cell cDNA in a range 
from 2 ng/reaction to 16 pg/reaction (1:10 – 1:1250). R2≥ 0.99 for all primers. 
 
 
 
Real-time quantitative PCR of recombinant BMP15 treated (100 ng/ml) in 
vitro matured bovine cumulus oocyte complex cDNA showed a statistically 
significant increase in expression of PTGS2 and TSG6 transcripts from the 
hBMP15 treated groups compared to the untreated control by a post-hoc 
Dunnett’s test. HAS2 and PTX3 showed no significant difference among 
treatment with p > 0.05 for ANOVA tests. With respect to expression of TSG6, 
there were also differences between treatments as tested by Tukey/Kramer HSD 
comparison of each pair. Treatments were labeled based on statistical grouping 
A, B or AB. hBMP15 was the only member of group A and FBK rbFL-BMP15 
treated oocytes were grouped into AB. HEK-293 produced rbFL-BMP15 was not 
  
	  
62	  
different from the control with both treatments placed in group B. (Fig. 15) (Table 
4) 
 
 
 
 
Figure 15 mRNA expression fold change relative to control treatment for BMP15 
stimulated genes. Gene Expression at 24 hours of in vitro maturation as 
calculated by ΔΔCT with GAPDH and YWHAZ as reference genes and untreated 
samples as a control. Data represents 3 biological replicates of 50 cumulus 
oocyte complexes per treatment with each analysis of each replicate completed 
at least two times. Treatment with 100 ng/ml recombinant human BMP15 
resulted in statistically significant increases in transcript levels of PTGS2 and 
TSG6. Treatments marked with * are statistically different from the control 
treatment by a post-hoc Dunnett’s test. Treatments with letters are statistically 
different from other letter within the same gene. p < 0.05 for all tests. Error bars 
represent +/- SEM of the expression values. 
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Table 4 mRNA expression results of in vitro matured cumulus oocyte complexes 
relative to control treatment for BMP15 stimulated genes. Values correspond to 
the bars in Figure 15. Treatments marked with * are statistically different from 
the control treatment by a post-hoc Dunnett’s test. 
 
 mRNA Expression 
Treatment  HAS2  PTGS2  PTX3  TSG6 
hBMP15  0.92 *1.79  1.33 *1.85 
HEK-293  1.02  1.22  1.09  0.95 
FBK  1.01  1.40  1.25  1.32 
Control  1.00  1.00  1.00  1.00 
 
 
 
Discussion 
We hypothesized that due to amino acid sequence divergence and species-
specific post-translational modifications, homologous BMP15 will be more 
effective at directing bovine oocyte development during in vitro maturation than 
heterologous BMP15 (Hashimoto, Moore, et al., 2005). Evidence of this 
difference in post-translational modifications was evident in the results combined 
from anti-FLAG Western blots and MALDI-TOF. Western blots revealed that 
rbFL-BMP15 produced by the HEK-293 cell line was present in two distinct 
forms, 17.1 and 15.4 kDa, with the second band of lower size not present in 
products from the bovine FBK cell line. The presence of two bands was not 
unexpected since it had been previously reported that recombinant human 
BMP15 produced by HEK-293 cells can be visualized as two bands by western 
blotting (Li, Rajanahally, et al., 2009). It was highly interesting, however, that the 
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homologous rbFL-BMP15 seemed to only be present at the higher molecular 
weight.  
MALDI-TOF analysis will accurately determine the mass of protein samples 
in relation to charge. The results are reported as mass over charge and 
therefore have to be interpreted based on the number of charges. A peak 
corresponding to 15.5 kDa was noted in the HEK-293 purified protein along with 
a species with 2 charges at 7.75 kDa. These peaks were absent in the product 
from the FBK cell line with only multiply charged species corresponding to a 17.1 
kDa protein. Where the human cell line produced 2 distinct molecular weight 
proteins, the bovine cell line produced only the larger. This evidence suggests 
the bovine (FBK) cell line completes any post-translational modifications, likely 
N-linked glycosylation (Hashimoto, Moore, et al., 2005), prior to secretion from 
the cell. Since post-translational modifications can be crucial to a protein’s 
function, consideration should be given to the host and cell type one might use 
for recombinant protein production. 
We have shown evidence of the biological function of rbFL-BMP15 produced 
by human and bovine cell lines by detection of phosphorylated-SMAD 1/5, as 
part of the canonical BMP signaling pathway, and inhibition by the selective 
inhibitor dorsomorphin. Analysis of genes activated by the phosphorylated 
SMAD 1/5 transcription factor by reverse transcription quantitative real-time PCR 
(RT-qPCR), however, showed only a modest increase in transcript levels at 24 
hours. These results are in contrast to research reported in the mouse with 
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granulosa cell culture treated with 100 ng/ml rhBMP15 or recombinant N-
terminal tagged rhBMP15 (Li, Rajanahally, et al., 2009). This level of rbBMP15 
or rhBMP15 may not be sufficient for a similar induction of transcription for 
downstream targets of phosphorylated SMAD 1/5. The timing of COC RNA 
collection after IVM for qPCR analysis could have also had an effect, for 
example Li et al. reported an increase in mRNA expression of mouse granulosa 
cells following treatment with recombinant human BMP15 at 5 hours of 
treatment (Li, Rajanahally, et al., 2009). There could have been a difference in 
mRNA transcript levels prior to the 24 hour time point used in this study that was 
undetectable at 24 hours. The time point for collection was chosen based on a 
standard IVM maturation protocol and transit times for the oocytes to arrive from 
their collection point to the laboratory for analysis. 
Gilchrist et al. reported an increase of 17%, from 41% to 58%, blastocyst rate 
with the addition of 10%, by volume, conditioned medium containing 
recombinant ovine BMP15 produced in a human cell line (HEK-293) (Gilchrist & 
Thompson, 2007). In this report, fifteen oocytes were collected from each of the 
three rounds of in vitro maturation were fertilized, cultured and blastocyst rates 
were recorded. There was no increase in blastocyst rate between the treatments, 
correlating with the minimal change in transcript levels as measured by RT-
qPCR. Based on species differences in OSF activity and the previous report in a 
bovine system using mouse GDF9 and sheep BMP15, the lack of a strong 
response could be attributable to a decreased role of endogenous BMP15 in lieu 
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of GDF9 similar what has been described in the mouse (Yan, Wang, et al., 2001; 
Yoshino, McMahon, et al., 2006).  
It was recently discovered that human GDF9 is secreted in a latent form, that 
can be activated by modifying the base sequence to result in an single amino 
acid change, in contrast to secreted active sheep GDF9 (Simpson, Stanton, et 
al., 2012).  Considering the significant differences in activity among species, it is 
plausible that endogenous bovine GDF9 signaling through SMAD 2/3 may be, in 
fact, more active during the final stages of maturation than BMP15 in the bovine 
model. The methods described here were designed to reduced variables, where 
possible, by using a known concentration of homologous recombinant mature 
protein purified by affinity chromatography. 
We have developed a system for the repeatable production of purified rbFL-
BMP15 from two different cell lines. These cell lines are an important resource 
for understanding the role of homologous BMP15 added to in vitro maturation 
medium and the influence of differential post-translational modifications. In this 
report, we failed to detect a significant affect of rbFL-BMP15 on the gene 
expression of in vitro mature cumulus oocyte complexes.  Due to resource 
limitations, this study only evaluated one time point, 24 hours, and one 
concentration, 100 ng/ml, therefore several other experiments could be 
conducted in the future to more completely ascertain the potential role of rbFL-
BMP15 in improving the in vitro maturation procedure. 
  
	  
67	  
Bone morphogenic proteins produced by the oocyte have been shown to 
prevent cumulus cell apoptosis (Hussein, Froiland, et al., 2005). A 
demonstration of this anti-apoptotic affect on cumulus cells by a TUNEL would 
corroborate the biological function of the recombinant proteins as measured by 
phosphorylation of SMAD 1/5. 
Alternatively, measurement of SMAD 1/5/8 phosphorylation could be 
detected with a luciferase assay (Mottershead, Pulkki, et al., 2008). This method 
would allow one to more easily and definitively observe the phosphorylation 
response from each of the recombinant proteins and their inhibition by 
dorsomorphin. The possibility of increased responsiveness of SMAD 
phosphorylation by signaling through a heterodimer of BMP15 with its proregion 
could also be investigated by comparing the conditioned medium response to 
the purified rbFL-BMP15 at levels too low for adequate detection by Western 
blotting of nuclear lysates. The rbFL-BMP15 construct could also be modified to 
include a FLAG tag on the proregion to purify both fragments for heterodimer 
testing. 
Different concentrations of BMP15 should be explored to determine the 
optimal response from the cumulus oocyte complexes as well as several time 
points. Transcripts activated by phosphorylated SMAD 1/5/8 may be detectable 
at earlier time points than 24 hours. Obtaining abattoir-derived ovaries from a 
local source and aspirating abattoir-derived oocytes at the laboratory would most 
easily accomplish the objective of measuring the response of downstream genes 
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at earlier time points by RT-qPCR. In this manner, several concentrations of 
rhBMP15 and rbFL-BMP15 from both cell lines could be tested for efficacy. 
The systems and information described here have the potential to impact the 
understanding of in vitro maturation of bovine oocytes and well as an 
understanding of the active role that oocytes play in deciding the fate of the 
follicle. Even a modest increase in development rates for in vitro culture of 
bovine embryos would increase the number of transferrable embryos available 
to a producer from a single oocyte collection, reflecting a significant savings of 
time and money. The possibility of improving culture conditions for oocytes and 
embryos reaches even to human medicine as the incidence of assisted 
reproductive technologies become more common. The Barker hypothesis 
suggests that adverse environmental conditions during fetal development may 
lead to adult diseases later in life including cardiovascular disease and diabetes 
(Barker, Bull, et al., 1990; Barker, 2001). Scientific evidence involving human 
and animal studies suggests that the Barker hypothesis may also pertain to 
exposure to insults during oocyte growth and maturation, fertilization and/or 
early embryonic development (Blondin, Farin, et al., 2000; Eppig & O'Brien, 
1998; Leese, Donnay, et al., 1998). Further investigation into the optimization in 
vitro culture during the critical stages of oocyte maturation and pre-implantation 
development will lead to greater culture efficiency and understanding of the 
important interactions between the developing oocyte/embryo and its 
environment. 
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A novel system was recently developed for a more physiological maturation 
of bovine and mouse cumulus oocyte complexes named SPOM, or stimulated 
physiological oocyte maturation (Albuz, Sasseville, et al., 2010). This method 
incorporates a two-step maturation process consisting of a 1-2 hour pre-IVM 
phase, where COCs are incubated with agents that cause a rapid increase in 
cAMP to prevent premature maturation, followed by an extended IVM period of 
18-22 hours with a phosphodiesterase (PDE) inhibitor and FSH. The results 
obtained from the SPOM system were comparable to in vivo matured and IVF 
processed embryos with a blastocyst rate of 69% and a fetal yield of 26%. The 
high levels of cAMP induced in the cumulus cells during the pre-IVM period 
intend to mimic the environment of the follicle and the continued addition of PDE 
inhibitors at low concentrations during the extended IVM phase were utilized to 
slow the pace of meiotic maturation. In context of the SPOM system, the 
addition of recombinant homologous OSFs to the pre-IVM stage would be 
appropriate to further mimic the physiological environment of the antral follicle 
increase the effectiveness of the in vitro maturation procedure by assisting in the 
blockage of cumulus cell apoptosis and contributing to a more complete 
cytoplasmic maturation.  
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CHAPTER IV 
SUMMARY 
 
In vitro systems for mammalian embryo production have been shown to 
produce lower quality embryos than those derived from in vivo sources. Recent 
reports have demonstrated that in vitro bovine oocyte maturation systems 
benefit from the addition of oocyte secreted factors, specifically GDF9 and 
BMP15 from heterologous sources (sheep or mouse) (Gilchrist & Thompson, 
2007; Hussein, Sutton-McDowall, et al., 2011; Hussein, Thompson, et al., 2006). 
The goal of this work was to produce a species-specific recombinant oocyte 
secreted factor with the potential to improve mammalian embryo production in 
vitro. 
Due to the high specificity of immunoprecipitation, we chose to produce 
recombinant bovine BMP15 with a FLAG tag in bovine and human cell lines. The 
FLAG purification system from Sigma has the advantage of elution without the 
use of denaturing. A PCR strategy was designed based on planned 
modifications of the transcript at the N-terminus end, cleavage site and C-
terminus. For expression in mammalian cell lines, rbFL-BMP15 was inserted into 
the multiple cloning site of PCDNA 3 designed for high expression in mammalian 
hosts with the human cytomegalovirus immediate-early (CMV) promoter. 
Following transfection and selection, we were able to repeatedly collect protein 
at a final concentration of 5-10 ng/µl in 100 µl TBS + 1% BSA, which allowed us 
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to easily add rbFL-BMP15 at a final concentration of 100 ng/ml media for in vitro 
maturation testing. The concentration and consistency obtained using this 
approach suggests a system that could be suitable for a number of mammalian 
recombinant protein targets where species-specific post-translational 
modifications are required. 
We hypothesized that due to amino acid sequence divergence and 
species-specific post-translational glycosylation, homologous BMP15 would be 
more effective at directing bovine oocyte development during in vitro maturation 
than heterologous BMP15 derived from human sources. Evidence of this 
difference in post-translational modifications was evident in the results combined 
from anti-FLAG Western blots and MALDI-TOF. These observations suggest 
that the bovine (FBK) cell line completes any post-translational modifications, 
likely N-linked glycosylation, prior to secretion from the cell. Since post-
translational modifications can be crucial to a protein’s function, consideration 
should be given to the host of the cell type one might use for recombinant 
protein production.  
We have shown evidence of the biological function of rbFL-BMP15 by 
detection of phosphorylated-SMAD 1/5, as part of the canonical BMP signaling 
pathway, and inhibition by the selective inhibitor dorsomorphin. Analysis of 
genes activated by the phosphorylated SMAD 1/5 transcription factor by reverse 
transcription quantitative real-time PCR (RT-qPCR), however, showed no 
statistically significant increase in transcript levels at 24 hours. Measurable 
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increases in stimulated gene transcripts may be detectable at earlier time points, 
so it would be interesting to profile gene expression of the COCs over the time 
course of IVM in the presence or absence of rbFL-BMP15. Considering the 
significant differences in activity among species, it is plausible that endogenous 
GDF9 may be, in fact, more active during the final stages of maturation than 
BMP15 in the bovine model. As such, the next step to investigation of the role of 
homologous OSFs in bovine IVM would be the production of recombinant FLAG 
tagged bovine GDF9 in the same manner as described here. Investigation of the 
effects of GDF9 alone, or in combination with BMP15, could help us draw 
conclusions about the bioactivity of these proteins in combination and 
specifically the possibility of a biologically active heterodimer formed between 
bovine GDF9 and BMP15. 
Here, we have developed a system for the repeatable production of 
purified rbFL-BMP15 from two different cell lines that could be easily transferred 
to many other members of the TGFβ family of proteins. The cell lines produced 
here are an important resource for understanding the role of homologous 
BMP15 added during in vitro maturation of bovine COCs and the influence of 
differential post-translational modifications on the biological activity of these 
products, especially if combined with the production of recombinant bovine 
GDF9.  
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